Summary
This study compared a new tablet form of colestipol with colestipol granules in patients with moderate to severe hypercholesterolaemia, in a double-blind, double-dummy, randomised multicentre trial conducted at hospital medical or lipid clinics. The subjects, 102 men and 93 women with serum low density lipoprotein (LDL) levels ≥ 4.3 mmol/L and triglyceride levels ≤ 3.0 mmol/L, followed a diet equivalent to the American Heart Association step I diet for 8 weeks. They were subsequently randomised to twice-daily 4g doses of colestipol tablets and 2 packets of placebo granules or to 2 packets of colestipol granules (4g twice daily) and placebo tablets for 8 weeks. The main outcome measures were lipid levels, compliance and adverse effects. Reductions in LDL cholesterol levels of 17.4% in the tablet group and 18.6% in the granules group were highly statistically significant (p = 0.0001), and did not differ between the tablet and granules groups. Increases in levels of triglycerides and high density lipoprotein cholesterol were small, not statistically significant and similar in both groups. Compliance was 89.4% in the tablet group and 87.3% in the granules group. Mild gastrointestinal adverse effects were frequent (> 50%) and similarly prevalent in both groups, but serious gastrointestinal adverse effects, such as obstruction, did not occur. This study demonstrated that low-dose colestipol tablets are as effective and safe as colestipol granules during short term treatment of moderate to severe hypercholesterolaemia.
Similar content being viewed by others
References
Dorr AE, Gundersen K, Schneider JC, et al. Colestipol hydrochloride in hypercholesterolemic patients. Effect on serum cholesterol and mortality. J Chron Dis 1978; 31: 5–14
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: 1. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64
Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007–12
Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA 1990; 264: 3013–7
National Cholesterol Education Program. Second Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1329–445
The International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113–56
West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 1980; 1: 873–5
Illingworth DR. Lipid-lowering drugs, an overview of indications and optimum therapeutic use. Drugs 1987; 6: 51–4
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–74
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–509
Schlierf G, Mrozik K, Heuck CC, et al. ‘Low dose’ colestipol in children, adolescents and young adults with familial hypercholesterolaemia. Atherosclerosis 1982; 41: 133–8
Superko HR, Grenland P, Manchester RA, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992; 70: 135–40
Tonstad S, Ose L, Gørbitz C, et al. Effectiveness of low-dose lovastatin combined with low-dose colestipol in moderate to severe primary hypercholesterolaemia. Scand J Clin Lab Invest 1993; 53: 457–63
Lyons D, Webster J, Fowler G, et al. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br J Clin Pharmacol 1994; 37: 59–62
Sweeney ME, Fletcher BJ, Rice CR, et al. Efficacy and compliance with cholestyramine bar versus granules in the treatment of hyperlipidemia. Am J Med 1991; 90: 469–73
Insull W, Davidson MH, Demke DM, et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis 1995; 112: 223–35
Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993; 328: 1213–9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tonstad, S., Bing, R.F., Frohlich, J. et al. Effectiveness of Colestipol Tablets vs Granules in Patients with Moderate to Severe Hypercholesterolaemia. Clin. Drug Invest. 10, 257–263 (1995). https://doi.org/10.2165/00044011-199510050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199510050-00002